- Home
- CR vs PCVX Comparison
CR vs PCVX Comparison
Compare CR & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CR
- PCVX
- Stock Information
- Founded
- CR 1855
- PCVX 2013
- Country
- CR United States
- PCVX United States
- Employees
- CR N/A
- PCVX N/A
- Industry
- CR Metal Fabrications
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- CR Industrials
- PCVX Health Care
- Exchange
- CR Nasdaq
- PCVX Nasdaq
- Market Cap
- CR 10.4B
- PCVX 4.0B
- IPO Year
- CR N/A
- PCVX 2020
- Fundamental
- Price
- CR $190.83
- PCVX $40.80
- Analyst Decision
- CR Strong Buy
- PCVX Strong Buy
- Analyst Count
- CR 5
- PCVX 8
- Target Price
- CR $223.60
- PCVX $114.17
- AVG Volume (30 Days)
- CR 298.9K
- PCVX 1.5M
- Earning Date
- CR 10-27-2025
- PCVX 11-05-2025
- Dividend Yield
- CR 0.49%
- PCVX N/A
- EPS Growth
- CR 37.96
- PCVX N/A
- EPS
- CR 6.25
- PCVX N/A
- Revenue
- CR $2,268,100,000.00
- PCVX N/A
- Revenue This Year
- CR $10.74
- PCVX N/A
- Revenue Next Year
- CR $10.97
- PCVX N/A
- P/E Ratio
- CR $30.12
- PCVX N/A
- Revenue Growth
- CR 19.64
- PCVX N/A
- 52 Week Low
- CR $127.04
- PCVX $27.66
- 52 Week High
- CR $203.89
- PCVX $116.00
- Technical
- Relative Strength Index (RSI)
- CR 54.23
- PCVX 47.89
- Support Level
- CR $187.49
- PCVX $43.12
- Resistance Level
- CR $193.65
- PCVX $45.90
- Average True Range (ATR)
- CR 5.12
- PCVX 1.86
- MACD
- CR 0.18
- PCVX -0.59
- Stochastic Oscillator
- CR 43.70
- PCVX 15.01
About CR Crane Company
Crane is a diversified industrial firm that manufactures a broad range of products, including valves, pumps, aerospace components, and fiberglass-reinforced plastic panels. Its business is organized into two segments: aerospace and electronics, and process flow technologies. Crane generated approximately $2.1 billion in revenue in 2024.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.